Research News

---

Topic: Hormonal Therapies (view all topics)

Tags for topic Hormonal Therapies:

• After surgery (also called "adjuvant")
• Arimidex
• Aromasin
• Aromatase Inhibitors
• Before surgery (also called "neoadjuvant")
• Evista
• Fareston
• Faslodex
• Femara
• Not applicable (no surgery)
• Planning Hormonal Therapy
• Prophylactic (to lower risk if you've never been diagnosed with breast cancer)
• Selective Estrogen Receptor Modulators
• Tamoxifen

View articles by month and year

• SERM Hormonal Therapy Medicines Help Reduce Risk in Women at High Risk, But Aren’t Widely Used

  Published on May 21, 2013 at 7:32 am

  • Tags: Selective Estrogen Receptor Modulators, Evista, Tamoxifen, and Prophylactic (to lower risk if you've never been diagnosed with breast cancer)

  A new study underscores the effectiveness of SERM hormonal therapy medicines to reduce breast cancer risk, but also found that they aren’t widely used because of concerns about side effects.

• High-Risk Women Often Don’t Take Risk Reducing Medicines Because of Side Effects

  Published on May 7, 2013 at 5:32 am

  • Tags: Selective Estrogen Receptor Modulators, Evista, Tamoxifen, and Prophylactic (to lower risk if you've never been diagnosed with breast cancer)

  A report written for the U.S. Preventive Services Task Force says that many women at high risk of breast cancer don’t take medicines that can lower that risk because of side effects.

• About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy

  Published on April 19, 2013 at 4:55 am

  • Tags: Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Arimidex, Aromasin, Femara, Tamoxifen, and After surgery (also called "adjuvant")

  A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.